Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, et al: The global burden of women's cancers: A grand challenge in global health. Lancet. 389:847–860. 2017. View Article : Google Scholar

GLOBOCAN, . 2020.New global cancer data. https://www.uicc.org/news/globocan-2020-new-global-cancer-dataNovember 24–2021

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar

Hall CS, Valad L and Lucci A: Circulating tumor cells in breast cancer patients. Crit Rev Oncog. 21:125–139. 2016. View Article : Google Scholar

Green M and Hortobagyi GN: Neoadjuvant chemotherapy for operable breast cancer. Oncology (Williston Park). 16:871–884. 889–890. 892–904. 997–998. 2002.

Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 52:1551–1557. 1983. View Article : Google Scholar

Gilbey AM, Burnett D, Coleman RE and Holen I: The detection of circulating breast cancer cells in blood. J Clin Pathol. 57:903–911. 2004. View Article : Google Scholar

Cueva Bañuelos JF, Rodríguez López C, Cortegoso Mosquera A, Palacios Ozores P and Curiel García T: Clinical relevance and therapeutic application of CTCs in advanced breast cancer. Adv Exp Med Biol. 1220:147–164. 2020. View Article : Google Scholar

Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, Cardoso MJ, Peccatori F, Paonessa D, Benares A, et al: Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). Breast. 39:131–138. 2018. View Article : Google Scholar

Weiss L: Metastasis of cancer: A conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 19:193–383. 2000. View Article : Google Scholar

Wittekind C and Neid M: Cancer invasion and metastasis. Oncology. 69 (Suppl 1):S14–S16. 2005. View Article : Google Scholar

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar

Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, et al: Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 16:4402014. View Article : Google Scholar

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V and Mavroudis D: Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 14:2593–2600. 2008. View Article : Google Scholar

Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM and Krishnamurthy S: Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol. 13:688–695. 2012. View Article : Google Scholar

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J and Pantel K: Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 18:5701–5710. 2012. View Article : Google Scholar

Enderling H, Hlatky L and Hahnfeldt P: Migration rules: Tumours are conglomerates of self-metastases. Br J Cancer. 100:1917–1925. 2009. View Article : Google Scholar

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L and Massagué J: Tumor self-seeding by circulating cancer cells. Cell. 139:1315–1326. 2009. View Article : Google Scholar

Pantel K and Speicher MR: The biology of circulating tumor cells. Oncogene. 35:1216–1224. 2016. View Article : Google Scholar

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–889. 2012. View Article : Google Scholar

Bae SY, Kamalanathan KJ, Galeano-Garces C, Konety BR, Antonarakis ES, Parthasarathy J, Hong J and Drake JM: Dissemination of circulating tumor cells in breast and prostate cancer: Implications for early detection. Endocrinology. 165:bqae0222024. View Article : Google Scholar

Alix-Panabières C and Pantel K: Challenges in circulating tumour cell research. Nat Rev Cancer. 14:623–631. 2014. View Article : Google Scholar

Coumans FAW, Ligthart ST, Uhr JW and Terstappen LWMM: Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 18:5711–5718. 2012. View Article : Google Scholar

Mego M and Reuben JM: Prognostic and predictive role of circulating tumor cells in breast cancer. Curr Breast Cancer Rep. 6:251–259. 2014. View Article : Google Scholar

Kanwar N and Done SJ: Molecular profiling and significance of circulating tumor cell based genetic signatures. Adv Exp Med Biol. 994:143–167. 2017. View Article : Google Scholar

Mego M, Mani SA and Cristofanilli M: Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol. 7:693–701. 2010. View Article : Google Scholar

Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang D, Luo D, Huang Y, Feng Y and Wang N: Circulating tumor cells in the early detection of human cancers. Int J Biol Sci. 18:3251–3265. 2022. View Article : Google Scholar

Ju S, Chen C, Zhang J, Xu L, Zhang X, Li Z, Chen Y, Zhou J, Ji F and Wang L: Detection of circulating tumor cells: Opportunities and challenges. Biomark Res. 10:582022. View Article : Google Scholar

Cristofanilli M: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 33 (3 Suppl 9):S9–S14. 2006. View Article : Google Scholar

Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, et al: Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin oncol. 23:1420–1430. 2005. View Article : Google Scholar

Alix-Panabières C and Pantel K: Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6:479–491. 2016. View Article : Google Scholar

Lianidou ES and Markou A: Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin Chem. 57:1242–1255. 2011. View Article : Google Scholar

Andree KC, van Dalum G and Terstappen LWMM: Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol. 10:395–407. 2016. View Article : Google Scholar

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K and Fehm T; DETECT study group, : Prognostic impact of circulating tumor cells assessed with the CellSearch system^™ and AdnaTest breast^™ in metastatic breast cancer patients: The DETECT study. Breast Cancer Res. 14:R1182012. View Article : Google Scholar

Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11:R462009. View Article : Google Scholar

Danila DC, Samoila A, Patel C, Schreiber N, Herkal A, Anand A, Bastos D, Heller G, Fleisher M and Scher HI: Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mrna in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients. Cancer J. 22:315–320. 2016. View Article : Google Scholar

Gorges TM, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse SA and Pantel K: Improved detection of circulating tumor cells in metastatic colorectal cancer by the combination of the CellSearch^® system and the AdnaTest^®. PLoS One. 11:e01551262016. View Article : Google Scholar

Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, et al: Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA. 106:3970–3975. 2009. View Article : Google Scholar

Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M and Ionescu-Zanetti C: Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol. 6:528–538. 2013. View Article : Google Scholar

Cho H, Kim J, Jeon CW and Han KH: A disposable microfluidic device with a reusable magnetophoretic functional substrate for isolation of circulating tumor cells. Lab Chip. 17:4113–4123. 2017. View Article : Google Scholar

Liu Z, Fusi A, Klopocki E, Schmittel A, Tinhofer I, Nonnenmacher A and Keilholz U: Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med. 9:702011. View Article : Google Scholar

Naume B, Borgen E, Tøssvik S, Pavlak N, Oates D and Nesland JM: Detection of isolated tumor cells in peripheral blood and in BM: Evaluation of a new enrichment method. Cytotherapy. 6:244–252. 2004. View Article : Google Scholar

Habli Z, AlChamaa W, Saab R, Kadara H and Khraiche ML: Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities. Cancers (Basel). 12:19302020. View Article : Google Scholar

Tong B, Xu Y, Zhao J, Chen M, Xing J, Zhong W and Wang M: Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy. Oncotarget. 8:86615–86624. 2017. View Article : Google Scholar

Drucker A, Teh EM, Kostyleva R, Rayson D, Douglas S and Pinto DM: Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. PLoS One. 15:e02373082020. View Article : Google Scholar

Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, et al: Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer. 130:808–816. 2012. View Article : Google Scholar

Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, et al: Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol. 156:57–63. 2000. View Article : Google Scholar

Dolfus C, Piton N, Toure E and Sabourin JC: Circulating tumor cell isolation: The assets of filtration methods with polycarbonate track-etched filters. Chin J Cancer Res. 27:479–487. 2015.

Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, Lim WT, Han J, Bhagat AA and Lim CT: Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 3:12592013. View Article : Google Scholar

Tamminga M, Andree KC, Hiltermann TJN, Jayat M, Schuuring E, van den Bos H, Spierings DCJ, Lansdorp PM, Timens W, Terstappen LWMM and Groen HJM: Detection of circulating tumor cells in the diagnostic leukapheresis product of non-small-cell lung cancer patients comparing CellSearch^® and ISET. Cancers (Basel). 12:8962020. View Article : Google Scholar

Miller MC, Robinson PS, Wagner C and O'Shannessy DJ: The parsortix^™ cell separation system-A versatile liquid biopsy platform. Cytometry A. 93:1234–1239. 2018. View Article : Google Scholar

Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, Cathcart P, Hines J, Shamash J and Lu YJ: Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS One. 10:e01380322015. View Article : Google Scholar

Bankó P, Lee SY, Nagygyörgy V, Zrínyi M, Chae CH, Cho DH and Telekes A: Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol. 12:482019. View Article : Google Scholar

Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, Thorban S, Nekarda H and Siewert JR: Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 49:150–158. 2002. View Article : Google Scholar

Lagoudianakis EE, Kataki A, Manouras A, Memos N, Papadima A, Derventzi A, Zografos G, Papadopoulos S, Katergiannakis V and Konstadoulakis MM: Detection of epithelial cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal carcinoma patients using OncoQuick density gradient centrifugation system. J Surg Res. 155:183–190. 2009. View Article : Google Scholar

Gupta V, Jafferji I, Garza M, Melnikova VO, Hasegawa DK, Pethig R and Davis DW: ApoStream(^™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics. 6:241332012. View Article : Google Scholar

O'Shannessy DJ, Davis DW, Anderes K and Somers EB: Isolation of circulating tumor cells from multiple epithelial cancers with ApoStream(^®) for detecting (or monitoring) the expression of Folate receptor alpha. Biomark Insights. 11:7–18. 2016. View Article : Google Scholar

Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, et al: EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream^® in patients with breast cancer treated with primary systemic therapy. PLoS One. 15:e02299032020. View Article : Google Scholar

Wu S, Gu L, Qin J, Zhang L, Sun F, Liu Z, Wang Y and Shi D: Rapid label-free isolation of circulating tumor cells from patients' peripheral blood using electrically charged Fe₃O₄ nanoparticles. ACS Appl Mater Interfaces. 12:4193–4203. 2020. View Article : Google Scholar

Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar

Luc R, Tortorella SM, Ververis K and Karagiannis TC: Lactate as an insidious metabolite due to the Warburg effect. Mol Biol Rep. 42:835–840. 2015. View Article : Google Scholar

Zhu Z and Zhang YHP: In vitro metabolic engineering of bioelectricity generation by the complete oxidation of glucose. Metab Eng. 39:110–116. 2017. View Article : Google Scholar

Nasiri R, Shamloo A, Ahadian S, Amirifar L, Akbari J, Goudie MJ, Lee K, Ashammakhi N, Dokmeci MR, Di Carlo D and Khademhosseini A: Microfluidic-based approaches in targeted cell/particle separation based on physical properties: Fundamentalsand applications. Small. 16:e20001712020. View Article : Google Scholar

Burinaru TA, Avram M, Avram A, Mărculescu C, Ţîncu B, Ţucureanu V, Matei A and Militaru M: Detection of circulating tumor cells using microfluidics. ACS Comb Sci. 20:107–126. 2018. View Article : Google Scholar

Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 450:1235–1239. 2007. View Article : Google Scholar

Park MH, Reátegui E, Li W, Tessier SN, Wong KH, Jensen AE, Thapar V, Ting D, Toner M, Stott SL and Hammond PT: Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchange in a microfluidic chip. J Am Chem Soc. 139:2741–2749. 2017. View Article : Google Scholar

Zhang X, Zhu Z, Xiang N, Long F and Ni Z: Automated microfluidic instrument for label-free and high-throughput cell separation. Anal Chem. 90:4212–4220. 2018. View Article : Google Scholar

Wang J, Li Y, Wang R, Han C, Xu S, You T, Li Y, Xia J, Xu X, Wang D, et al: A fully automated and integrated microfluidic system for efficient CTC detection and its application in hepatocellular carcinoma screening and prognosis. ACS Appl Mater Interfaces. 13:30174–30186. 2021. View Article : Google Scholar

Lee J and Kwak B: Simultaneous on-chip isolation and characterization of circulating tumor cell sub-populations. Biosens Bioelectron. 168:1125642020. View Article : Google Scholar

Lee AC, Svedlund J, Darai E, Lee Y, Lee D, Lee HB, Kim SM, Kim O, Bae HJ, Choi A, et al: OPENchip: An on-chip in situ molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells. Lab Chip. 20:912–922. 2020. View Article : Google Scholar

Zhang Y, Li M, Gao X, Chen Y and Liu T: Nanotechnology in cancer diagnosis: Progress, challenges and opportunities. J Hematol Oncol. 12:1372019. View Article : Google Scholar

Huang Q, Yin W, Chen X, Wang Y, Li Z, Du S, Wang L and Shi C: Nanotechnology-based strategies for early cancer diagnosis using circulating tumor cells as a liquid biopsy. Nanotheranostics. 2:21–41. 2018. View Article : Google Scholar

Muthu MS and Feng SS: Theranostic liposomes for cancer diagnosis and treatment: Current development and pre-clinical success. Expert Opin Drug Deliv. 10:151–155. 2013. View Article : Google Scholar

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor cells: Biology and clinical significance. Sig Transduct Target Ther. 6:4042021. View Article : Google Scholar

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G and Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell. 13:58–68. 2008. View Article : Google Scholar

Hosseini H, Obradović MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M, et al: Early dissemination seeds metastasis in breast cancer. Nature. 540:552–558. 2016. View Article : Google Scholar

Rhim AD, Thege FI, Santana SM, Lannin TB, Saha TN, Tsai S, Maggs LR, Kochman ML, Ginsberg GG, Lieb JG, et al: Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology. 146:647–651. 2014. View Article : Google Scholar

Yamaguchi J, Kokuryo T, Yokoyama Y, Ebata T, Ochiai Y and Nagino M: Premalignant pancreatic cells seed stealth metastasis in distant organs in mice. Oncogene. 40:2273–2284. 2021. View Article : Google Scholar

Banys M, Hahn M, Gruber I, Krawczyk N, Wallwiener M, Hartkopf A, Taran FA, Röhm C, Kurth R, Becker S, et al: Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 144:531–538. 2014. View Article : Google Scholar

Shao X, Jin X, Chen Z, Zhang Z, Chen W, Jiang J, Wang Z, Cui Y, Fan WH, Wang K, et al: A comprehensive comparison of circulating tumor cells and breast imaging modalities as screening tools for breast cancer in Chinese women. Front Oncol. 12:8902482022. View Article : Google Scholar

Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, et al: HER2-positive circulating tumor cells in breast cancer. PLoS One. 6:e156242011. View Article : Google Scholar

Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga JY and Bidard FC: Circulating tumor cells in early breast cancer. JNCI Cancer Spectr. 3:pkz0262019. View Article : Google Scholar

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, et al: Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A meta-analysis. J Natl Cancer Inst. 110:560–567. 2018. View Article : Google Scholar

Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, et al: Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 106:dju0662014. View Article : Google Scholar

Janni WJ, Rack B, Terstappen LWMM, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, et al: Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res. 22:2583–2593. 2016. View Article : Google Scholar

Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A and Marty M: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 14:7004–7010. 2008. View Article : Google Scholar

Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S and Lucci A: Circulating tumor cells after neoadjuvant chemotherapy in stage I–III triple-negative breast cancer. Ann Surg Oncol. 22 (Suppl 3):S552–S558. 2015. View Article : Google Scholar

Hwang SB, Bae JW, Lee HY and Kim HY: Circulating tumor cells detected by RT-PCR for CK-20 before surgery indicate worse prognostic impact in triple-negative and HER2 subtype breast cancer. J Breast Cancer. 15:34–42. 2012. View Article : Google Scholar

Azim HA Jr, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, et al: Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. Breast. 22:1060–1065. 2013. View Article : Google Scholar

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, et al: Improved circulating tumor cell detection by a combined EpCAM and MCAM cellsearch enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy. Mol Cancer Ther. 14:821–827. 2015. View Article : Google Scholar

Kasimir-Bauer S, Bittner AK, König L, Reiter K, Keller T, Kimmig R and Hoffmann O: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 18:202016. View Article : Google Scholar

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, et al: Circulating tumour cells and pathological complete response: Independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and −2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 28:103–109. 2017. View Article : Google Scholar

Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, et al: Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant ‘Geparquattro’ trial. Clin Cancer Res. 23:5384–5393. 2017. View Article : Google Scholar

Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M and Pierga JY: Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 21:729–733. 2009. View Article : Google Scholar

Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, Alran S, Giacchetti S, Marty M, Lebofsky R and Pierga JY: Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-Month analysis of the REMAGUS02 study. Int J Breast Cancer. 2013:1304702013. View Article : Google Scholar

Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, et al: Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 16:2634–2645. 2010. View Article : Google Scholar

Sparano J, O'Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, Sledge GW and Miller KD: Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 4:1700–1706. 2018. View Article : Google Scholar

Janni W, Rack BK, Fasching PA, Haeberle L, Tesch H, Lorenz R, Schochter F, Tzschaschel M, De Gregorio A, Fehm TN, et al: Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. J Clin Oncol. 36 (Suppl):S5152018. View Article : Google Scholar

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, et al: Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 111:380–387. 2019. View Article : Google Scholar

Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, et al: Clinical application of circulating tumor cells in breast cancer: Overview of the current interventional trials. Cancer Metastasis Rev. 32:179–188. 2013. View Article : Google Scholar

Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM and Lucci A: Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg. 223:20–29. 2016. View Article : Google Scholar

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 384:164–172. 2014. View Article : Google Scholar

Walter VP, Taran FA, Wallwiener M, Hahn M, Brucker SY and Hartkopf AD: Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. Arch Gynecol Obstet. 297:785–790. 2018. View Article : Google Scholar

Peeters DJE, van Dam PJ, Van den Eynden GGM, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, et al: Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer. 110:375–383. 2014. View Article : Google Scholar

Giordano A, Giuliano M, Hsu L, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN and Cristofanilli M: Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol. 28 (Suppl):S10002010. View Article : Google Scholar

Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW and Hayes DF: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 12:6403–6409. 2006. View Article : Google Scholar

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, et al: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 13:R672011. View Article : Google Scholar

Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, et al: Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 23:1144–1150. 2012. View Article : Google Scholar

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, et al: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol. 15:406–414. 2014. View Article : Google Scholar

Lv Q, Gong L, Zhang T, Ye J, Chai L, Ni C and Mao Y: Prognostic value of circulating tumor cells in metastatic breast cancer: A systemic review and meta-analysis. Clin Transl Oncol. 18:322–330. 2016. View Article : Google Scholar

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV and Terstappen LW: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 12:4218–4224. 2006. View Article : Google Scholar

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, et al: Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. Clin Breast Cancer. 7:471–479. 2007. View Article : Google Scholar

Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Diéras V, Mathiot C, Mignot L, Thiery JP, Sastre-Garau X and Pierga JY: Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol. 19:496–500. 2008. View Article : Google Scholar

Yagata H, Nakamura S, Toi M, Bando H, Ohno S and Kataoka A: Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan. Int J Clin Oncol. 13:252–256. 2008. View Article : Google Scholar

De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, et al: Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 27:3303–3311. 2009. View Article : Google Scholar

Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM and Isaacs C: Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 27:5153–5159. 2009. View Article : Google Scholar

Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM and Cristofanilli M: Circulating tumor cells in metastatic inflammatory breast cancer. Annals Oncol. 20:1824–1828. 2009. View Article : Google Scholar

De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, et al: Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals Oncol. 21:33–39. 2010. View Article : Google Scholar

Consoli F, Grisanti S, Amoroso V, Almici C, Verardi R, Marini M and Simoncini E: Circulating tumor cells as predictors of prognosis in metastatic breast cancer: Clinical application outside a clinical trial. Tumori. 97:737–742. 2011. View Article : Google Scholar

Hartkopf AD, Wagner P, Wallwiener D, Fehm T and Rothmund R: Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res. 31:979–984. 2011.

Tokudome N, Ito Y, Takahashi S, Kobayashi K, Taira S, Tsutsumi C, Oto M, Oba M, Inoue K, Kuwayama A, et al: Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Breast Cancer. 18:195–202. 2011. View Article : Google Scholar

De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN and Cristofanilli M: Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 12:264–269. 2012. View Article : Google Scholar

Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M and Ueno NT: Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. 17:96–104. 2012. View Article : Google Scholar

Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C and Bidard FC: High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Annals Oncol. 23:618–624. 2012. View Article : Google Scholar

Weissenstein U, Schumann A, Reif M, Link S, Toffol-Schmidt UD and Heusser P: Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer. 12:2062012. View Article : Google Scholar

Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, et al: Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial. Annals Oncol. 24:2766–2772. 2013. View Article : Google Scholar

Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, Li S, Hu Z, Wu S, Liu B and Jiang Z: Circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable prognostic and predictive biomarker. BMC Cancer. 13:2022013. View Article : Google Scholar

Tarhan MO, Gonel A, Kucukzeybek Y, Erten C, Cuhadar S, Yigit SC, Atay A, Somali I, Dirican A, Demir L and Koseoglu M: Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev. 14:1725–1729. 2013. View Article : Google Scholar

Turker I, Uyeturk U, Sonmez OU, Oksuzoglu B, Helvaci K, Arslan UY, Budakoglu B, Alkis N, Aksoy S and Zengin N: Detection of circulating tumor cells in breast cancer patients: Prognostic predictive role. Asian Pac J Cancer Prev. 14:1601–1607. 2013. View Article : Google Scholar

Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, et al: The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat. 137:503–510. 2013. View Article : Google Scholar

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al: The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Crit Rev Oncol Hematol. 134:39–45. 2019. View Article : Google Scholar

Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, et al: Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. J Natl Cancer Inst. 113:443–452. 2021. View Article : Google Scholar

Sundling KE and Lowe AC: Circulating tumor cells: Overview and opportunities in cytology. Adv Anat Pathol. 26:56–63. 2019. View Article : Google Scholar

Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jörgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K and Rydén L: Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 20:482018. View Article : Google Scholar

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, et al: Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Res. Treat. 173:155–165. 2019.

Cabel L, Berger F, Cottu P, Loirat D, Rampanou A, Brain E, Cyrille S, Bourgeois H, Kiavue N, Deluche E, et al: Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: The randomised CirCe01 trial. Br J Cancer. 124:1207–1213. 2021. View Article : Google Scholar

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, et al: Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin oncol. 32:3483–3489. 2014. View Article : Google Scholar

Bidard FC, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, Bachelot T, Bourgeois H, Gonçalves A, Ladoire S, et al: Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: The STIC CTC randomized clinical trial. JAMA Oncol. 7:34–41. 2021. View Article : Google Scholar

Jacot W, Cottu P, Berger F, Dubot C, Venat-Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V, Luporsi E, et al: Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: The CirCe T-DM1 trial. Breast Cancer Res. 21:1212019. View Article : Google Scholar

Fehm T, Müller V, Banys-Paluchowski M, Fasching PA, Friedl TWP, Hartkopf AD, Huober J, Loehberg C, Rack B, Riethdorf S, et al: Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells-results from the randomized phase III DETECT III trial. Cancer Res. 81 (4 Suppl):PD3–12. 2021. View Article : Google Scholar

Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 30:587–592. 2012. View Article : Google Scholar

Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G and Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 20:1499–1504. 2009. View Article : Google Scholar

Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA and Purdie CA; Breast Recurrence in Tissues Study Group, : Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The breast recurrence in tissues study (BRITS). Breast Cancer Res. 12:R922010. View Article : Google Scholar

Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, et al: Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 22:2227–2233. 2011. View Article : Google Scholar

Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM and Sneige N: Stability of HER2-positive status in breast carcinoma: A comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol. 22:1547–1553. 2011. View Article : Google Scholar

Sari E, Guler G, Hayran M, Gullu I, Altundag K and Ozisik Y: Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol. 28:57–63. 2011. View Article : Google Scholar

Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB and Thompson AM: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 38:708–714. 2012. View Article : Google Scholar

Chang HJ, Han SW, Oh DY, Im SA, Jeon YK, Park IA, Han W, Noh DY, Bang YJ and Kim TY: Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 41:593–599. 2011. View Article : Google Scholar

Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF and Guarneri V: Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: A single-institution analysis. Ann Oncol. 24:101–108. 2013. View Article : Google Scholar

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L and Bergh J: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 30:2601–2608. 2012. View Article : Google Scholar

Alix-Panabières C and Pantel K: Circulating tumor cells: Liquid biopsy of cancer. Clin Chem. 59:110–118. 2013. View Article : Google Scholar

Schochter F, Friedl TWP, deGregorio A, Krause S, Huober J, Rack B and Janni W: Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions. Cells. 8:14122019. View Article : Google Scholar

Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, et al: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 6:1002992021. View Article : Google Scholar

Paoletti C, Regan MM, Liu MC, Marcom PK, Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, et al: Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI phase 2 trial. Cancer Res. 77 (4 Suppl):P1-01-01. 2017. View Article : Google Scholar

Salu P and Reindl KM: Advancements in circulating tumor cell research: Bridging biology and clinical applications. Cancers (Basel). 16:12132024. View Article : Google Scholar

Smit DJ, Schneegans S and Pantel K: Clinical applications of circulating tumor cells in patients with solid tumors. Clin Exp Metastasis. 41:403–411. 2024. View Article : Google Scholar

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY and Bidard FC: Circulating tumor cells: Clinical validity and utility. Int J Clin Oncol. 22:421–430. 2017. View Article : Google Scholar